Thirty two cases of rheumatoid arthritis were treated with multi-glycosides of Tripterygium wilfordii (T2) in a dosage of 30 mg daily for 12 weeks. Significant improvements in clinical and laboratory variables were observed. In comparison with the results of routine dose of T2 (60 mg per day) treatment, there was no significant difference to be seen between the two treatment plans. Meanwhile, symptom of rash and slightly alimentary canal lower incidences and milder manifestations of side effects of T2 were found in the patients of low dose group than in that of routine dose group. It is suggested that it is reasonable to choose the dose of 30 mg daily as the routine treatment for rheumatoid arthritis patients.
'/%3e%3cuse xlink:href='%23a' transform='rotate(23.036 .093 25.536)'/%3e%3cuse xlink:href='%23a' transform='rotate(45.87 1.273 16.18)'/%3e%3cuse xlink:href='%23a' transform='rotate(69.945 .996 12.078)'/%3e%3cuse xlink:href='%23a' transform='rotate(20.66 -19.689 31.932)'/%3e%3c/svg%3e)
'/%3e%3cuse xlink:href='%23a' transform='rotate(60)'/%3e%3ccircle r='17' fill='%23000095'/%3e%3ccircle r='15' fill='%23fff'/%3e%3c/svg%3e)
'/%3e%3cuse xlink:href='%23a' transform='translate(288.889 -214.211)'/%3e%3cuse xlink:href='%23a' transform='translate(108 342.749)'/%3e%3cuse xlink:href='%23a' transform='translate(469.189 342.749)'/%3e%3c/svg%3e)
